


BUSINESS SUMMARY:

Phyxiom is an analytics platform that transforms the clinical outcomes of patients with uncontrolled asthma and COPD. Phyxiom offers a unique solution for the 12 million people who suffer from uncontrolled asthma in the US through its 100% digital business model that is device and medication independent and delivered by a proven world-class team of clinical and technology professionals. The Phyxiom technology is the result of 10 years' of clinical research at RCSI developing a family of patented algorithms and software platforms for the management of chronic respiratory disease.

TEAM:



Prof Richard Costello
Co-Founder



John Byrne
Business Co-founder

INDUSTRY: Digital Health

DATE FOUNDED: 2021

COMPANY STAGE: Seed

CONTACT

Prof Richard Costello
Co-Founder
E: rcostello@rcsi.com

Dr Conor MacCormack
RCSI, Spin out Company Manager
Email: conormaccormack@rcsi.ie

MARKET OPPORTUNITY:


- Uncontrolled asthma affects over 12 million people in the US alone. This leads to substantial healthcare costs and impact on quality of life.
- Uncontrolled asthma is characterised by poor symptom control and need for costly emergency steroids and/or hospitalisation.
- 48% of patients have uncontrolled Asthma, yet incur 80% of asthma care costs in the US each year.
- Phyxiom has invented a solution with identified savings of \$13.5B p.a. for payers from the total US spend of \$64 Bn p.a.

MARKET READINESS

- Commercially ready, in use in Ireland with the HSE. US market entry planned in 2025
- Future expansion opportunities focusing on COPD in the US and asthma/COPD in Europe and Asia
- Validated patient outcomes from 10 years of clinical trial data resulting in three patented algorithms

CUTTING EDGE TECHNOLOGY:

- Phyxiom has developed a remote diagnostics platform, which is device independent, integrating smart inhalers and spirometry devices to patient data for time-based analysis.
- The platform acts as an intelligent decision support system for physicians delivering patient clinical data in an easily accessible form.
- Supports precise diagnosis and treatment of uncontrolled asthma using patient's own data measured over time
- The platform manages the process end-to-end. Achieving a seamless integration to any physician electronic patient record and billing system.
- A prescription issued by the physician results in a seamless delivery of devices to the patient. Physician has continuous diagnosis of the patient condition and treatment plan. Payer can rely on evidence based treatment data for seamless re-imbursement to the physician.



INVESTMENT:

- Seed Round €1.7M
- EIS eligible
- Validated revenue model